## Protocol Section
### Identification Module
**NCT ID:** NCT01031979

**Brief Title:** Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine

**Official Title:** Psychophysiology of Prolonged Exposure for PTSD With/Without Yohimbine

#### Organization Study ID Info
**ID:** CDA-2-013-09F
#### Organization
**Class:** FED
**Full Name:** VA Office of Research and Development
### Status Module
#### Completion Date
**Date:** 2015-07-07

**Type:** ACTUAL

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2018-02-07

**Type:** ACTUAL

**Last Update Submit Date:** 2018-01-10

**Overall Status:** COMPLETED

#### Primary Completion Date
**Date:** 2015-04-01

**Type:** ACTUAL

#### Results First Post Date
**Date:** 2017-02-24

**Type:** ACTUAL

**Results First Submit Date:** 2016-11-03

**Results First Submit QC Date:** 2017-01-03

#### Start Date
**Date:** 2010-12-01

**Type:** ACTUAL

**Status Verified Date:** 2018-01

#### Study First Post Date
**Date:** 2009-12-15
**Type:** ESTIMATED
**Study First Submit Date:** 2009-12-04
**Study First Submit QC Date:** 2009-12-14
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** FED

**Name:** VA Office of Research and Development

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Is US Export:** True

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** The proposed study has three distinct but related research objectives. The first goal is to measure physiological correlates of successful treatment with Prolonged Exposure (PE) therapy for posttraumatic stress disorder (PTSD) in veterans of the Iraq and Afghanistan wars. Individuals with PTSD often experience elevated heart rates and other objectively measurable signs of anxiety when confronted with safe situations that remind them of past dangerous situations. We will measure physiological responses and compare the outcomes to patient's self reported subjective accounts of symptom improvement on traditional measures of PTSD. Developing a way to measure objective gains in symptoms improvement may help researchers who are studying ways to improve PTSD treatment. The second goal of the study is to investigate if yohimbine, a drug found to promote a specific type of learning, will improve treatment outcomes for veterans in PTSD treatment. The third goal is to investigate if ability to get used to loud startling audio tones correlates to baseline PTSD pathology and treatment outcomes for PE. This goal represents an important step forward in understanding characteristics of heritable traits that are related PTSD. It is significant because such research may one day lead to the development of individual responder policies that will assist patients by individualizing treatment plans based on personal characteristics.

**Detailed Description:** The proposed study has three distinct but related research objectives. The first research goal is to measure psychophysiological correlates of treatment gains associated with Prolonged Exposure (PE) therapy for PTSD in veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF). Specifically, heart rate, heart rate variability, skin conductance, and facial electromyography, will be recorded before and after treatment during a three minute anxiety probe specific to the patient's index trauma. These measures will be compared to patient's self reported subjective accounts of symptom improvement on traditional measures of PTSD pathology (Subjective Units of Distress (SUDs), PTSD Checklist-Military Version (PCL), Clinician Administered PTSD Scale (CAPS), and the Beck Depression Inventory (BDI)). This goal is significant for veterans because currently no widely used objective criteria exist to measure treatment progress in PTSD. While the preponderance of existing evidence suggests that no one objective psychophysiological measurement will be a valid correlate for all individuals, even establishing a measurement paradigm that can show mean differences between groups will provide researchers with an objective tool to measure outcomes on clinical trials.

The second goal of the study is to investigate if the administration of yohimbine, a drug found to promote the extinction of conditioned fear in animal models, and more recently, in humans with claustrophobia, improves the facilitation of fear extinction in PE. Yohimbine is a safe drug that is already extensively used in human populations. Specifically, this goal will be investigated using a double blind placebo controlled randomized trial design. The hypothesis is that one 21mg oral dose of yohimbine given concurrently with a 40 minute imaginal exposure exercise in PE will lead to a greater reduction in cue-induced anxiety during the following weekly PE session than placebo. This goal is significant because current projections of PTSD in OEF/OIF veterans indicate that the need for psychological services will likely outpace the supply of such services. Accordingly, assisting treatments to be more efficient will likely translate into more veterans receiving much needed mental health services.

The 3rd goal is to investigate if ability to habituate to loud, 95db, audio tones correlates to baseline PTSD pathology and treatment outcomes for PE. This goal represents an important step forward in understanding characteristics of trait habituation, fear extinction, and learning in humans, which are all factors related to the successful treatment of PTSD. It is also significant because such research may lead to the development of individual responder policies that will assist veterans by individualizing treatment plans based on personal characteristics.

### Conditions Module

**Conditions:**

- Post-Traumatic Stress Disorder

**Keywords:**

- PTSD

- Prolonged Exposure

- extinction

- habituation

- psychophysiology

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** QUADRUPLE

**Who Masked:**

- PARTICIPANT

- CARE_PROVIDER

- INVESTIGATOR

- OUTCOMES_ASSESSOR

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 26

**Type:** ACTUAL

**Phases:**

- PHASE2

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

**Intervention Names:**

- Drug: Yohimbine

**Label:** Yohimbime Group

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

**Intervention Names:**

- Drug: Placebo

**Label:** Placebo Group

**Type:** PLACEBO_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Yohimbime Group

**Description:** alpha-2 adrenergic receptor antagonist

**Name:** Yohimbine

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Placebo Group

**Description:** Placebo

**Name:** Placebo

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** The primary outcome was trauma-cued heart rate reactivity a week after the drug visit as measured by the PTSD Brief Reactivity (PBR) task. For each patient, a 3-minute trauma script was constructed containing vivid details of the target trauma and used in tandem with a standard neutral script for baseline measurement. Heart rate reactivity for each time point was the beats per minute (BPM) difference between the neutral and trauma scripts represented as a slope.

**Measure:** Trauma-Cued Heart Rate Reactivity

**Time Frame:** One week after drug visit

#### Secondary Outcomes

**Description:** The CAPS is a structured interview for diagnosis of PTSD and is widely considered the gold-standard assessment. The CAPS produces a total score ranging from 0-136, with higher scores indicating more severe PTSD symptom severity. A 15-point decrease is considered clinically significant.

**Measure:** Change in Clinician Administered PTSD Scale (CAPS) Score

**Time Frame:** 0 Weeks, 15 weeks

**Description:** The PCL is a 17-item self-report measure of PTSD symptom severity based on the DSM-IV and has adequate psychometric properties. The PCL produces a score range between 17-85, with higher scores indicating more distress related to PTSD symptoms. A 10-point decrease on the PCL is considered clinically significant.

**Measure:** Change in Post Traumatic Stress Disorder Checklist (PCL) Score

**Time Frame:** 0 weeks, 15 weeks

**Description:** The BDI-II is a 21-item self-report measure that assesses depressive behavioral symptoms. It has demonstrated adequate psychometric validity, and external validity and is used widely as the dependent variable in treatment outcomes research. The BDI-II produces score ranges from 0-63, with higher scores indicating more severe depression symptom severity. A 5-point decrease on the BDI-II is considered clinically significant.

**Measure:** Change in Becks Depression Inventory (BDI-II) Score

**Time Frame:** 0 weeks, 15 weeks

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Subjects must be competent to provide informed consent for research participation.
* Subjects must be male veterans and post deployed active duty male personnel of OEF/OIF.
* Subjects must be between the ages of 18 and 45.
* Subjects must meet DSM-IV diagnostic criteria for PTSD on the CAPS.
* For subjects taking SSRI's, subjects must be stabilized on the current prescribed dose for a period of at least 14 days prior to the trial and remain at that dose for the remainder of the study. Subjects who change their SSRI status or dosage during the study will continue to receive services via the study resources but data generated will not be used in analyses. Subjects will be eligible for the study if they are willing to titrate off potentially confounding agents prior to yohimbine administration (for a period of five half-lives), given that such titration is also clinically appropriate and deemed to be in the patient's best interests.

Exclusion Criteria:

* Subjects with a recent (\< 2 month) history of psychiatric hospitalization or suicide attempt. Recent work with veterans with severe mental illness suggests that a 2-month period of stabilization is sufficient to minimize risk and possible relapse (Frueh, 2005). Subjects with an existing diagnosis of schizophrenia or other Axis I serious mental illnesses (SMI, besides PTSD) will be excluded. SMI will include any severe and persistent mental illness.
* Subjects with a current diagnosis of drug dependence, due to potential interactions with study measurements and treatments. Alcohol use disorders will be allowed given that subjects can pass exclusion criterion 12 without withdrawal symptoms.
* Subjects with any acute illness or fever. Individuals who otherwise meet study criteria will be rescheduled for evaluation for participation.
* Subjects with evidence of or a history of clinically significant hematological, endocrine, cardiovascular, hepatic, pulmonary, renal, gastrointestinal, or neurological disease including diabetes, as these conditions may affect physiological/subjective responses.
* Subjects with SCID-diagnosed panic disorder, as yohimbine may precipitate panic attacks.
* Subjects with an abnormal ECG.
* Subjects with a blood pressure of 140/90 or higher, as yohimbine has been shown to elevate blood pressure.
* Subjects taking Beta blockers, alpha-adrenergic agents, Beta-agonist inhalers, opiates or opiate antagonists and any psychotropic medications other than SSRI's because these may affect test response.
* Subjects who are unwilling or unable to maintain abstinence for three days prior to yohimbine administration from over-the-counter drugs with sympathomimetic properties, e.g., asthma medications, cold medicines with ephedrine, dietary supplements with ephedrine alkaloids, and illegal drugs, e.g., amphetamines, methamphetamine, cocaine, and MNDA as well as alcohol because these may exacerbate the action of yohimbine.
* Subjects taking alpha-adrenergic antagonists, e.g. prazosin for hypertension; and beta-adrenergic antagonists, e.g. propranolol. Because they may attenuate effects of yohimbine. Subjects will be eligible for the study if they are willing to titrate off potentially confounding agents prior to yohimbine administration (for a period of five half-lives), given that such titration is also clinically appropriate and deemed to be in the patient's best interests.
* Asthmatic subjects and subjects on medications for hypertension, due to criteria 9 and 10.

These inclusion/exclusion criteria will allow the majority of veterans treated in the PCT to be study eligible. Accordingly, the sample will be likely generalizable to the population of interest.

**Gender Based:** True

**Gender Description:** Males only.

**Maximum Age:** 45 Years

**Minimum Age:** 18 Years

**Sex:** MALE

**Standard Ages:**

- ADULT

### Contacts Locations Module

#### Locations

**Location 1:**

**City:** Charleston

**Country:** United States

**Facility:** Ralph H. Johnson VA Medical Center, Charleston, SC

**State:** South Carolina

**Zip:** 29401-5799

#### Overall Officials

**Official 1:**

**Affiliation:** Ralph H. Johnson VA Medical Center, Charleston, SC

**Name:** Peter W. Tuerk, PhD MA BA

**Role:** PRINCIPAL_INVESTIGATOR

### IPD Sharing Statement Module

**IPD Sharing:** NO

### References Module

#### References

**Citation:** Keller SM, Tuerk PW. Evidence-based psychotherapy (EBP) non-initiation among veterans offered an EBP for posttraumatic stress disorder. Psychol Serv. 2016 Feb;13(1):42-8. doi: 10.1037/ser0000064. Epub 2015 Dec 14.

**PMID:** 26654474

**Citation:** Yuen EK, Gros DF, Price M, Zeigler S, Tuerk PW, Foa EB, Acierno R. Randomized Controlled Trial of Home-Based Telehealth Versus In-Person Prolonged Exposure for Combat-Related PTSD in Veterans: Preliminary Results. J Clin Psychol. 2015 Jun;71(6):500-12. doi: 10.1002/jclp.22168. Epub 2015 Mar 25.

**PMID:** 25809565

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000068099

- Term: Trauma and Stressor Related Disorders

- ID: D000001523

- Term: Mental Disorders

### Condition Browse Module - Browse Branches

- Abbrev: BXM

- Name: Behaviors and Mental Disorders

- Abbrev: All

- Name: All Conditions

- Abbrev: BC26

- Name: Wounds and Injuries

### Condition Browse Module - Browse Leaves

- ID: M16103

- Name: Stress Disorders, Post-Traumatic

- Relevance: HIGH

- As Found: Post Traumatic Stress Disorder

- ID: M24916

- Name: Stress Disorders, Traumatic

- Relevance: HIGH

- As Found: Traumatic Stress Disorder

- ID: M17685

- Name: Wounds and Injuries

- Relevance: LOW

- As Found: Unknown

- ID: M222

- Name: Trauma and Stressor Related Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M4815

- Name: Mental Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M14473

- Name: Psychotic Disorders

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000040921

- Term: Stress Disorders, Traumatic

- ID: D000013313

- Term: Stress Disorders, Post-Traumatic

### Intervention Browse Module - Ancestors

- ID: D000009184

- Term: Mydriatics

- ID: D000001337

- Term: Autonomic Agents

- ID: D000018373

- Term: Peripheral Nervous System Agents

- ID: D000045505

- Term: Physiological Effects of Drugs

- ID: D000058669

- Term: Adrenergic alpha-2 Receptor Antagonists

- ID: D000000317

- Term: Adrenergic alpha-Antagonists

- ID: D000018674

- Term: Adrenergic Antagonists

- ID: D000018663

- Term: Adrenergic Agents

- ID: D000018377

- Term: Neurotransmitter Agents

- ID: D000045504

- Term: Molecular Mechanisms of Pharmacological Action

- ID: D000064804

- Term: Urological Agents

### Intervention Browse Module - Browse Branches

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: Urol

- Name: Urological Agents

- Abbrev: HB

- Name: Herbal and Botanical

### Intervention Browse Module - Browse Leaves

- ID: M20746

- Name: Adrenergic Agents

- Relevance: LOW

- As Found: Unknown

- ID: M20755

- Name: Adrenergic Antagonists

- Relevance: LOW

- As Found: Unknown

- ID: M29195

- Name: Adrenergic alpha-2 Receptor Antagonists

- Relevance: LOW

- As Found: Unknown

- ID: M17752

- Name: Yohimbine

- Relevance: HIGH

- As Found: Laparoscopic appendectomy

- ID: M12139

- Name: Mydriatics

- Relevance: LOW

- As Found: Unknown

- ID: M3669

- Name: Adrenergic alpha-Antagonists

- Relevance: LOW

- As Found: Unknown

- ID: M20504

- Name: Neurotransmitter Agents

- Relevance: LOW

- As Found: Unknown

- ID: T332

- Name: Yohimbe

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: D000015016

- Term: Yohimbine

### Misc Info Module

- Version Holder: 2024-05-24

## Results Section

### Adverse Events Module

#### Event Groups

**Group ID:** EG000

**Title:** Yohimbine Group

**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

Yohimbine: alpha-2 adrenergic receptor antagonist

**ID:** EG000

**Other Num at Risk:** 12

**Serious Number At Risk:** 12

**Title:** Yohimbine Group

**Group ID:** EG001

**Title:** Placebo Group

**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

Placebo: Placebo

**ID:** EG001

**Other Num at Risk:** 12

**Serious Number At Risk:** 12

**Title:** Placebo Group

**Frequency Threshold:** 0

## Results Section - Baseline Characteristics Module

### Denomination Counts

**Group ID:** BG000

**Value:** 12

**Group ID:** BG001

**Value:** 12

**Group ID:** BG002

**Value:** 24

**Units:** Participants

### Group

**ID:** BG000

**Title:** Yohimbine Group

**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

Yohimbine: alpha-2 adrenergic receptor antagonist

### Group

**ID:** BG001

**Title:** Placebo Group

**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

Placebo: Placebo

### Group

**ID:** BG002

**Title:** Total

**Description:** Total of all reporting groups

### Measure

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 0

#### Measurement

**Group ID:** BG002

**Value:** 0

**Category Title:** <=18 years

#### Measurement

**Group ID:** BG000

**Value:** 12

#### Measurement

**Group ID:** BG001

**Value:** 12

#### Measurement

**Group ID:** BG002

**Value:** 24

**Category Title:** Between 18 and 65 years

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 0

#### Measurement

**Group ID:** BG002

**Value:** 0

**Category Title:** >=65 years

**Class Title:** 

### Measure

#### Measurement

**Group ID:** BG000

**Lower Limit:** 18

**Upper Limit:** 45

**Value:** 34.6

#### Measurement

**Group ID:** BG001

**Lower Limit:** 18

**Upper Limit:** 45

**Value:** 29.9

#### Measurement

**Group ID:** BG002

**Lower Limit:** 18

**Upper Limit:** 45

**Value:** 32.4

**Class Title:** 

### Measure

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 0

#### Measurement

**Group ID:** BG002

**Value:** 0

**Category Title:** Female

#### Measurement

**Group ID:** BG000

**Value:** 12

#### Measurement

**Group ID:** BG001

**Value:** 12

#### Measurement

**Group ID:** BG002

**Value:** 24

**Category Title:** Male

**Class Title:** 

### Measure

#### Measurement

**Group ID:** BG000

**Value:** 12

#### Measurement

**Group ID:** BG001

**Value:** 12

#### Measurement

**Group ID:** BG002

**Value:** 24

**Class Title:** United States

**Denomination Units Selected:** 

## Results Section - Baseline Characteristics Module

### Measure 1
**Parameter Type:** COUNT_OF_PARTICIPANTS
**Title:** Age, Categorical
**Unit of Measure:** Participants
### Measure 2
**Dispersion Type:** FULL_RANGE
**Parameter Type:** MEAN
**Title:** Age, Continuous
**Unit of Measure:** years
### Measure 3
**Parameter Type:** COUNT_OF_PARTICIPANTS
**Title:** Sex: Female, Male
**Unit of Measure:** Participants
### Measure 4
**Parameter Type:** NUMBER
**Title:** Region of Enrollment
**Unit of Measure:** participants
**Population Description:** 14 participants were randomized to the yohimbine group; however only 12 completed the primary outcome assessment at session 4 and were able to be analyzed.
## Results Section - More Information Module
### Certain Agreement
**PI Sponsor Employee:** True
### Point of Contact
**Email:** peter.tuerk@va.gov
**Organization:** Ralph H. Johnson VAMC
**Phone:** (843) 789-6188
**Title:** Dr. Peter Tuerk
## Results Section - Outcome Measures Module
### Outcome Measure 1
#### Analysis
**CI Lower Limit:** -2.29
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -0.59
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY_OR_OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Beta
**Parameter Value:** -1.44
**Statistical Comment:** 
**Statistical Method:** mixed effects/hierarchical linear model
**Tested Non-Inferiority:** 
### Outcome Measure 2
#### Analysis
**CI Lower Limit:** 
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 
**CI Upper Limit:** 
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY_OR_OTHER
**Other Analysis Description:** 
**P-Value:** .39
**P-Value Comment:** 
**Parameter Type:** Slope
**Parameter Value:** -0.87
**Statistical Comment:** 
**Statistical Method:** Hierarchical Linear Modeling
**Tested Non-Inferiority:** 
### Outcome Measure 3
#### Analysis
**CI Lower Limit:** 
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 
**CI Upper Limit:** 
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY_OR_OTHER
**Other Analysis Description:** 
**P-Value:** .58
**P-Value Comment:** 
**Parameter Type:** Slope
**Parameter Value:** -0.55
**Statistical Comment:** 
**Statistical Method:** Hierarchical Linear Modeling
**Tested Non-Inferiority:** 
### Outcome Measure 4
#### Analysis
**CI Lower Limit:** -2.71
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -0.49
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY_OR_OTHER
**Other Analysis Description:** 
**P-Value:** .03
**P-Value Comment:** 
**Parameter Type:** Beta
**Parameter Value:** -1.60
**Statistical Comment:** 
**Statistical Method:** Hierarchical Linear Modeling
**Tested Non-Inferiority:** 
## Results Section
### Outcome Measures Module
#### Outcome Measure 1
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 3.84
- **Upper Limit:** 
- **Value:** 71.01
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 3.11
- **Upper Limit:** 
- **Value:** 75.08
**Title:** 
#### Outcome Measure 2
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 24.49
- **Upper Limit:** 
- **Value:** 67.33
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 13.01
- **Upper Limit:** 
- **Value:** 65.00
**Title:** 
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 14.93
- **Upper Limit:** 
- **Value:** 25.13
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 10.84
- **Upper Limit:** 
- **Value:** 20.62
**Title:** 
#### Outcome Measure 3
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 12.49
- **Upper Limit:** 
- **Value:** 64.00
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 14.53
- **Upper Limit:** 
- **Value:** 60.25
**Title:** 
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 6.63
- **Upper Limit:** 
- **Value:** 27.37
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 8.88
- **Upper Limit:** 
- **Value:** 28.50
**Title:** 
#### Outcome Measure 4
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 13.10
- **Upper Limit:** 
- **Value:** 30.56
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 7.05
- **Upper Limit:** 
- **Value:** 22.62
**Title:** 
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 5.68
- **Upper Limit:** 
- **Value:** 7.00
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 7.97
- **Upper Limit:** 
- **Value:** 7.87
**Title:** 
## Results Section
### Outcome Measures Module
#### Outcome Measure 1
**Description:** The primary outcome was trauma-cued heart rate reactivity a week after the drug visit as measured by the PTSD Brief Reactivity (PBR) task. For each patient, a 3-minute trauma script was constructed containing vivid details of the target trauma and used in tandem with a standard neutral script for baseline measurement. Heart rate reactivity for each time point was the beats per minute (BPM) difference between the neutral and trauma scripts represented as a slope.
**Dispersion Type:** Standard Error
**Parameter Type:** MEAN
**Reporting Status:** POSTED
**Time Frame:** One week after drug visit
**Title:** Trauma-Cued Heart Rate Reactivity
**Type:** PRIMARY
**Unit of Measure:** beats per minute
##### Group
**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

Yohimbine: alpha-2 adrenergic receptor antagonist
**ID:** OG000
**Title:** Yohimbine Group
##### Group
**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

Placebo: Placebo
**ID:** OG001
**Title:** Placebo Group
#### Outcome Measure 2
**Description:** The CAPS is a structured interview for diagnosis of PTSD and is widely considered the gold-standard assessment. The CAPS produces a total score ranging from 0-136, with higher scores indicating more severe PTSD symptom severity. A 15-point decrease is considered clinically significant.
**Dispersion Type:** Standard Deviation
**Parameter Type:** MEAN
**Reporting Status:** POSTED
**Time Frame:** 0 Weeks, 15 weeks
**Title:** Change in Clinician Administered PTSD Scale (CAPS) Score
**Type:** SECONDARY
**Unit of Measure:** units on a scale
##### Group
**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

Yohimbine: alpha-2 adrenergic receptor antagonist
**ID:** OG000
**Title:** Yohimbine Group
##### Group
**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

Placebo: Placebo
**ID:** OG001
**Title:** Placebo Group
#### Outcome Measure 3
**Description:** The PCL is a 17-item self-report measure of PTSD symptom severity based on the DSM-IV and has adequate psychometric properties. The PCL produces a score range between 17-85, with higher scores indicating more distress related to PTSD symptoms. A 10-point decrease on the PCL is considered clinically significant.
**Dispersion Type:** Standard Deviation
**Parameter Type:** MEAN
**Reporting Status:** POSTED
**Time Frame:** 0 weeks, 15 weeks
**Title:** Change in Post Traumatic Stress Disorder Checklist (PCL) Score
**Type:** SECONDARY
**Unit of Measure:** units on a scale
##### Group
**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

Yohimbine: alpha-2 adrenergic receptor antagonist
**ID:** OG000
**Title:** Yohimbine Group
##### Group
**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

Placebo: Placebo
**ID:** OG001
**Title:** Placebo Group
#### Outcome Measure 4
**Description:** The BDI-II is a 21-item self-report measure that assesses depressive behavioral symptoms. It has demonstrated adequate psychometric validity, and external validity and is used widely as the dependent variable in treatment outcomes research. The BDI-II produces score ranges from 0-63, with higher scores indicating more severe depression symptom severity. A 5-point decrease on the BDI-II is considered clinically significant.
**Dispersion Type:** Standard Deviation
**Parameter Type:** MEAN
**Reporting Status:** POSTED
**Time Frame:** 0 weeks, 15 weeks
**Title:** Change in Becks Depression Inventory (BDI-II) Score
**Type:** SECONDARY
**Unit of Measure:** units on a scale
##### Group
**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

Yohimbine: alpha-2 adrenergic receptor antagonist
**ID:** OG000
**Title:** Yohimbine Group
##### Group
**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

Placebo: Placebo
**ID:** OG001
**Title:** Placebo Group
### Participant Flow Module
#### Group
**Description:** Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.

Yohimbine: alpha-2 adrenergic receptor antagonist
**ID:** FG000
**Title:** Yohimbime Group
#### Group
**Description:** Patients will take a placebo one hour before first imaginal exposure in PE.

Placebo: Placebo
**ID:** FG001
**Title:** Placebo Group
#### Period
**Title:** Overall Study
##### Withdraw
**Type:** Lost to Follow-up
###### Reason
**Group ID:** FG000
**Number of Subjects:** 5
###### Reason
**Group ID:** FG001
**Number of Subjects:** 4
##### Milestone
**Type:** STARTED
###### Achievement
**Group ID:** FG000
**Number of Subjects:** 14
###### Achievement
**Group ID:** FG001
**Number of Subjects:** 12
##### Milestone
**Type:** Completed Primary Outcome Measure
###### Achievement
**Group ID:** FG000
**Number of Subjects:** 12
###### Achievement
**Group ID:** FG001
**Number of Subjects:** 12
##### Milestone
**Type:** COMPLETED
###### Achievement
**Group ID:** FG000
**Number of Subjects:** 9
###### Achievement
**Group ID:** FG001
**Number of Subjects:** 8
##### Milestone
**Type:** NOT COMPLETED
###### Achievement
**Group ID:** FG000
**Number of Subjects:** 5
###### Achievement
**Group ID:** FG001
**Number of Subjects:** 4
**Has Results:** True